Home › Tarix Granted Orphan Drug Status For TXA127
 

Keywords :   


Tarix Granted Orphan Drug Status For TXA127

2016-02-18 02:28:07| drugdiscoveryonline News Articles

Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company's lead compound, TXA127, for the treatment of laminin-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). Early-onset LAMA2-related muscular dystrophy occurs in approximately 1 in 30,000 individuals and accounts for between 30 and 40 percent of total cases of congenital muscular dystrophy.

Tags: status drug granted orphan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Amino updates Android STB portfolio with Amigo 7Y launch
07.11Sainsbury's and M&S warn Budget may push up prices
07.11VIZIO reports Q3 2024 financial results
07.11Farm Progress America, Nov. 7, 2024
07.11NanoTech Materials Named to TIMEs List of the Best Inventions of 2024
07.11Farm Progress America, Nov. 7, 2024
07.11ORF and ORS extend contract with SES at 19.2° East
07.11Victory+ to monetize over 60 new FAST channels with Amagi
More »